IP Library › Granted Patent US 11,147,780
Granted Patent B2
US 11,147,780 · App. 16/899,465 · Granted Oct 19, 2021

Multidrug pain management package

Inventors: David L. Steinberg (Boca Raton, FL); Joseph Loskove (Boca Raton, FL); Hannah Thompson (Boca Raton, FL)
Assignee: ALGIA PHARMA, LLC
A61K31/167A61J1/035A61K31/195A61M15/0003A61M15/0048A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,147,780
App. No.
16/899,465
Granted
Oct 19, 2021
Kind
B2
Abstract

Disclosed herein is a multidrug pain management package to dispense two or more medicaments to treat pain comprising a primary n-polygon, and one or more concentric m-polygons, wherein each side of the n-polygon and m-polygons have at least n or m-medicament chambers capable of holding the two or more medicaments. Also disclosed herein is a multidrug pain management package comprising a disk, wherein the disk is divided into equally spaced regions, and wherein each region has chambers capable of holding medicaments. Also disclosed herein are single formulations to treat pain.

Claims (49)

1. A single formulation consisting of:

a. acetaminophen;

b. one or more nonsteroidal anti-inflammatory drug;

c. a gabapentinoid; and

d. at least two additional active ingredients selected from the group consisting of:

alpha 2 agonists, corticosteroids, H2 blockers, proton pump inhibitors, antacids, SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin Norepinephrine Reuptake Inhibitors), sleep aids drugs, natural sleep aids, magnesium, zinc, vitamin C, vitamin D, and tramadol.

2. The single formulation of claim 1 , wherein the at least two additional active ingredients further comprises one or more of anti-convulsants and anti-seizure medications.

3. The single formulation of claim 1 , wherein the single formulation further comprises one or more excipients.

4. The single formulation of claim 1 , wherein the single formulation comprises 500 mg of acetaminophen, 50 mg of a nonsteroidal anti-inflammatory drug, 50 mg of gabapentinoid, and two or more active ingredients.

5. The single formulation of claim 1 , wherein the single formulation comprises 650 mg of acetaminophen, 100 mg of a nonsteroidal anti-inflammatory drug, 75 mg of a gabapentinoid, and two or more active ingredients.

6. The single formulation of claim 1 , wherein the single formulation comprises 1000 mg of acetaminophen, 100 mg of a nonsteroidal anti-inflammatory drug, 75 mg of gabapentinoid, and two or more active ingredients.

7. The single formulation of claim 1 , wherein the single formulation comprises 1000 mg of acetaminophen, 200 mg of a nonsteroidal anti-inflammatory drug, 75 mg of gabapentinoid, and two or more active ingredients.

8. The single formulation of claim 1 , wherein the single formulation is given to a patient on the first day every four hours.

9. A method of treating pain, consisting of administering the single formulation of claim 1 .

10. The method of claim 9 , wherein the single formulation comprises 500 mg of acetaminophen, 50 mg of a nonsteroidal anti-inflammatory drug, 50 mg of a gabapentinoid, and two or more active ingredients.

11. The method of claim 9 , wherein the single formulation comprises 650 mg of acetaminophen, 100 mg of a nonsteroidal anti-inflammatory drug, 75 mg of a gabapentinoid, and two or more active ingredients.

12. The method of claim 9 , wherein the non-steroidal anti-inflammatory drug is a COX-2 selective nonsteroidal anti-inflammatory drug.

13. The method of claim 9 , wherein the gabapentinoid is gabapentin.

14. The method of claim 9 , wherein the single formulation is used to treat a patient to manage pain associated with a COVID-19 infection.

15. The method of claim 9 , wherein the single formulation is used to treat a patient to manage pain, wherein the patient is also infected with COVID-19.

16. An inhaler to dispense the single formulation according to claim 1 .

17. A single formulation consisting of:

a. acetaminophen;

b. one or more nonsteroidal anti-inflammatory drug;

c. a gabapentinoid; and

d. at least two additional active ingredients selected from the group consisting of:

alpha 2 agonists, corticosteroids, H2 blockers, proton pump inhibitors, antacids, SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin Norepinephrine Reuptake Inhibitors), sleep aids drugs, natural sleep aids, magnesium, and tramadol, zinc, vitamin C, vitamin D, and tramadol,

and

wherein the single formulation is given to a patient on the first day every eight hours.

18. A single formulation consisting of:

a. acetaminophen;

b. one or more nonsteroidal anti-inflammatory drug;

c. a gabapentinoid; and

d. at least two additional active ingredients selected from the group consisting of:

alpha 2 agonists, corticosteroids, H2 blockers, proton pump inhibitors, antacids, SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin Norepinephrine Reuptake Inhibitors), sleep aids drugs, natural sleep aids, magnesium, zinc, vitamin C, vitamin D, and tramadol,

and

wherein the single formulation is dispensed by an inhaler to a patient.

19. A single formulation consisting of:

a. acetaminophen;

b. one or more nonsteroidal anti-inflammatory drug;

c. a gabapentinoid;

d. one or more corticosteroids; and

e. one or more H2 blockers.

20. A single formulation consisting of:

a. acetaminophen;

b. one or more nonsteroidal anti-inflammatory drug;

c. a gabapentinoid; and

d. at least two additional active ingredients selected from the group consisting of:

corticosteroids, H2 blockers, magnesium, zinc, vitamin C, and vitamin D.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2020
From: STEINBERG, DAVID L.; LOSKOVE, JOSEPH; THOMPSON, HANNAH
To: ALGIA PHARMA, LLC
Reel/Frame 053155/0363 →
Continuity (2)
Provisional Application 62980935 · Feb 24, 2020
Related Publication 20210259999A1 · Aug 26, 2021